Litcius/Paper detail

Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma

Lisa Haas, Anais Elewaut, Camille L. Gérard, Christian Umkehrer, Lukas Leiendecker, Malin Pedersen, Izabela Kręcioch, David Hoffmann, Maria Novatchkova, Mario Kuttke, Tobias Neumann, Inês Pires da Silva, Harriet Witthock, Michel A. Cuendet, Sebastian Carotta, Kevin J. Harrington, Johannes Zuber, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Olivier Michielin, Sakari Vanharanta, Thomas Wiesner, Anna C. Obenauf

2021Nature Cancer196 citationsDOIOpen Access PDF

Topics & Concepts

ImmunotherapyTumor microenvironmentMelanomaImmune systemCancer researchMAPK/ERK pathwayTargeted therapyMedicineDendritic cellImmunologyCancer immunotherapyCancerBiologySignal transductionInternal medicineBiochemistryImmunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersCAR-T cell therapy research
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma | Litcius